Keywords: as1413, achieves, remission, rate, aml, uk, cancer
AS1413 achieves 42% remission rate in AML
Article | 15 December 2008
UK cancer drug developer Antisoma says that 42% of patients taking its late-stage candidate AS1413 responded to treatment and entered remission, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
